References

• 1. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35–47.ArticlePubMed
• 2. Lim YS. Current status of liver disease in Korea: hepatitis C. Korean J Hepatol 2009;15:S25–S28.ArticlePubMed
• 3. Chung RT. Acute hepatitis C virus infection. Clin Infect Dis 2005;41:S14–S17.ArticlePubMed
• 4. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36:S35–S46.ArticlePubMed
• 5. Ishikawa T, Higuchi K, Kubota T, Seki K, Honma T, Yoshida T, et al. Combination PEG-IFN a-2b/Ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival. Hepatogastroenterology 2012;59:529–532.ArticlePubMed
• 6. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000;32:1131–1137.ArticlePubMed
• 7. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147–1171.ArticlePubMed
• 8. European Association for the Study of the Liver. EASL international consensus conference on hepatitis C. Paris, 26-28, February 1999, Consensus Statement. J Hepatol 1999;30:956–961.PubMed
• 9. Lee HS, Lee JH, Choi MS, Kim CY. Comparison of the incidence of hepatocellular carcinoma in HBV-and HCV-associated liver cirrhosis; A prospective study. Korean J Hepatol 1996;2:21–28.
• 10. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-born non-A, non-B viral hepatitis genome. Science 1989;244:359–362.PubMed
• 11. Lee HJ, Suh JI, Park CW. Efficacy of treatment with interferon alpha in hepatitis C. Korean J Hepatol 1996;2:166–175.
• 12. Yoon BC, Kim HJ, Kim KS, Yoo HD, Lee SU, Han BH. Therapeutic efficacy of combination therapy with Alpha Interferon and Ribavirin in chronic hepatitis C. Korean J Gastroenterol 2001;37:203–209.
• 13. Suh DJ, Park NH, Chung YH, Lee YS. Efficacy of combination of Interferon α 2a , Ribavirin and UDCA in the treatment of chronic hepatitis C. Korean J Hepatol 1998;4:109–119.
• 14. Choi WH, Paik SW, Choi MS, Lee JH, Koh KC, Yoo BC. Treatment of hepatitis C naive Patients according to EASL Recommendations in Korea. Korean J Hepatol 2003;9:S53.
• 15. Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–965.ArticlePubMed
• 16. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004;8:1–125.Article
• 17. Itakura J, Asahina Y, Tamaki N, Hirayama I, Yasui Y, Tanaka T, et al. Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy. Hepatol Res 2011;41:217–224.ArticlePubMed
• 18. Mach TH, Cieśla A, Warunek W, Janas-Skulina U, Cibor D, Owczarek D, et al. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b. Pol Arch Med Wewn 2011;121:434–439.ArticlePubMed
• 19. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666–1672.ArticlePubMed
• 20. Sinn DH, Shin SR, Kil JS, Kim J, Gwak GY, Choi MS, et al. Efficacy of peg-interferon-a-2a plus ribavirin for patients aged 60 years and older with chronic hepatitis C in Korea. J Gastroenterol Hepatol 2011;26:469–476.ArticlePubMed
• 21. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975–982.ArticlePubMed
• 22. Lee H, Choi MS, Paik SW, Kim JH, Kim DY, Lee JH, et al. Peginterferon Alfa-2a plus Ribavirin for initial treatment of chronic hepatitis C in Korea. Korean J Hepatol 2006;12:31–40.PubMed
• 23. Sinn DH, Paik SW, Kang P, Kil JS, Park SU, Lee SY, et al. Disease progression and the risk factor analysis for chronic hepatitis C. Liver Int 2008;28:1363–1369.ArticlePubMed
• 24. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009;24:336–345.ArticlePubMed
• 25. Jung YS, Park HB, Oak CH, Jang YK, Yun BC, Ahn SY, et al. The usefulness of histopathological severity index in predicting the response to Alpha-interferon in patients with chronic hepatitis C. Korean J Gastroenterol 1999;34:496–502.
• 26. Chew KW, Allen SA, Taylor LE, Rich JD, Feller E. Treatment outcomes with Pegylated interferon and Ribavirin for male prisoners with chronic hepatitis C. J Clin Gastroenterol 2009;43:686–691.ArticlePubMedPMC
• 27. Ferenci P, Brunner H, Laferl H, Scherzer TM, Maieron A, Strasser M, et al. A randomized, prospective trial of Ribavirin 400 mg/day versus 800 mg/day in combination with Peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology 2008;47:1816–1823.ArticlePubMed

Fig. 1

Virologic response of pegylated interferon and ribavirin. RVR 61.8%, EVR 82.5%, ETR 88.9%, SVR 80.5%.

Table 1

Baseline characteristics of study population

Table 2

The SVR according to RVR, EVR, EVR

Table 3

Odds ratio of several factors

Table 4

Factors influencing on SVR from univariate analysis

Table 5

Adverse events of therapy

Figure & Data

References

Citations

Citations to this article as recorded by